Dr. Shailesh R. Satpute, MD, PhD

Dr. Satpute practices at Northside Hospital Atlanta in Atlanta, Georgia, part of Northside Hospital.

Dr. Satpute's NPI, 1538460225, was assigned on November 11, 2010. Dr. Satpute graduated from Other in 2002. Dr. Satpute holds Georgia license 97026.

Dr. Satpute's primary practice is Northside Hospital Atlanta, at 1000 Johnson Ferry Road, NE, Atlanta, GA 30342 in Fulton County. The practice phone is (404) 851-8000.

Dr. Satpute's primary practice is Northside Hospital Atlanta in Atlanta, Georgia, part of Northside Hospital. Dr. Satpute is also affiliated with Northside Hospital Forsyth. The medical group on file is Northside Hospital Cancer Institute. Dmand AI also links Dr. Satpute to 2 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Satpute practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Satpute's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Satpute is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Satpute's licenses on file in 4 states: Georgia, Tennessee, Mississippi and Indiana.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Satpute treats.

CMS data shows 553 Medicare services from Dr. Satpute across 10 procedure codes in 2024, for 171 Medicare patients. Medicare paid $35,224 for them.

CMS counts 171 Medicare patients who saw Dr. Satpute in 2024. The largest group is 65 to 74, with 76 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Satpute's median patient age at 69, with 52% women.

In 2024, Dr. Satpute wrote 796 Medicare Part D claims for 126 patients. 80% of them were for generic drugs. CMS names the drug for 482 of them, across 20 drugs with 11 or more claims each, at $376,203 in total drug cost. In 2023, CMS named 1,364 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 71 out of 100 for Dr. Satpute for performance year 2024, reported as part of a group. Dr. Satpute accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Satpute as offering telehealth.

Dmand AI links 9 papers to Dr. Satpute, published from 2008 to 2020. The most frequent topics are T-Lymphocytes, Cytokines and Interferon-gamma. Dr. Satpute's most frequent co-authors are Folabi Ibrahim Ariganjoye, MD, Brian L. Berman, MD and Roy C. Fox, MD.

Dmand AI links Dr. Satpute to 6 clinical trials, 3 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Rectal Diseases. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 1,070 general payments to Dr. Satpute from 76 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Progenics Pharmaceuticals, Inc. paid the most, $5,040.

Dr. Satpute graduated from Other in 2002.

Dr. Satpute is in network with 20 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.